多奈哌齐
竞争对手
医学
耐受性
加药
不利影响
内科学
痴呆
药理学
麻醉
疾病
作者
David Wilkinson,Anthony Peter Passmore,Roger Bullock,Stephen Hopker,Robert C. Smith,Felix Potocnik,Catherine Maud,Ingrid Engelbrecht,Christoph Höck,John R. Ieni,Ranbir Bahra
标识
DOI:10.1111/j.1742-1241.2002.tb11294.x
摘要
SUMMARY This 12‐week, multinational study compared the tolerability and cognitive effects of donepezil (up to 10 mg once daily) and rivastigmine (up to 6 mg twice daily) in 111 patients with mild to moderate Alzheimer's disease. Both medications were administered open label according to recommended dosing regimens from the respective product labelling available during the conduct of the study. More patients in the donepezil group (89.3%) completed the study compared with the rivastigmine group (69.1%; p=0.009), and 10.7% of the donepezil group and 21.8% of the rivastigmine group discontinued due to adverse events (AEs); 87.5% of donepezil‐treated patients and 47.3% of rivastigmine‐treated patients remained on the maximum approved dose of each drug at the last study visit. Both groups showed comparable improvements on the ADAS‐cog administered by raters blind to study medication at weeks 4 and 12. Thus, using the recommended dosing schedules, donepezil was better tolerated with fewer discontinuations due to AEs, and both agents improved cognition to a similar extent.
科研通智能强力驱动
Strongly Powered by AbleSci AI